TABLE 1.
Randomized, controlled trials of antimicrobial agents for the treatment of infections caused by methicillin-resistant Staphylococcus aureus (MRSA)
| Reference (year) | n (total) | Evaluable patients with MRSA (n) | MRSA infections | Antimicrobial agents | Clinical success (%)* |
|---|---|---|---|---|---|
| 41 (1988) | 21 | 21 | 'Invasive', | Teicoplanin, | 7/12 (58) |
| septicemia | vancomycin | 6/9 (67) | |||
| 51 (1992) | 101 | 47 | Bacteremia, | TMP-SMX, | 21/21 (100) |
| skin or soft tissue | vancomycin | 26/26 (100) | |||
| 73 (1999) | 562 | 15 | Skin or soft tissue | Q/D, | 7/9 (78) |
| vancomycin | 3/6 (50) | ||||
| 76 (2000) | 171 | 38 | Nosocomial | Q/D, | 6/20 (31) |
| pneumonia | vancomycin | 8/18 (44) | |||
| 86 (2001) | 396 | 32 | Nosocomial | Linezolid, | 15/23 (65) |
| pneumonia | vancomycin | 7/9 (78) | |||
| 85 (2002) | 460 | 108 | Skin or soft tissue, | Linezolid, | 41/56 (73) |
| pneumonia, urinary tract | vancomycin | 38/52 (73) |
*
None of these studies demonstrated a statistically significant difference in outcomes (clinical success rates) between the comparator antimicrobial agents. Q/D Quinupristin-dalfopristin; TMP-SMX Trimethoprim-sulphamethoxazole